EZH2 and ovarian cancer: Following treatment of ovarian cancer cells with GSK126 to inhibit the methyltransferase activity of EZH2, no significant change was found in the expression of EZH2 in ovarian cancer cells compared with that in the control group, the level of H3K27me3 was decreased, and the expression of Et-miRNAs was upregulated (Figures 2C, D).